Piper Sandler raised the firm’s price target on Tango Therapeutics (TNGX) to $14 from $11 and keeps an Overweight rating on the shares. Following a flurry of updates from companies across its coverage, the firm updating its 2026 Catalyst Tracker, as well as several models and price targets.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNGX:
- Tango Therapeutics appoints new CEO amid leadership transition
- Tango Therapeutics announces retirement of CEO Weber, Peters to succeed
- Tango Therapeutics appoints Sung Lee to board of directors
- Tango Therapeutics Adds Independent Director to Strengthen Governance
- Strategic Positioning and Synergy Potential Drive Buy Rating for Tango Therapeutics’ Vopimetostat